Quinuclidines (including Unsaturation) Patents (Class 514/305)
  • Patent number: 10588895
    Abstract: Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 10421755
    Abstract: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 24, 2019
    Assignee: Novartis AG
    Inventors: Wolfgang Marterer, Mahavir Prashad, Edwin Bernard Villhauer, Liladhar Murlidhar Waykole, James Anthony Vivelo, Bertrand Sutter, Jean-Claude Bianchi, Raeann Wu, Denis Har, Piotr H. Karpinski, Massimo Pignone, Doris Stingelin, Eckart Buerger
  • Patent number: 10414762
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 17, 2019
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Joachim Luithle, Frank-Gerhard Böβ, Christina Erb, Katrin Schnizler, Timo Flessner, Marja van Kampen, Christoph Methfessel
  • Patent number: 10285952
    Abstract: Provided are methods, combinations and pharmaceutical compositions for treating or preventing an infection in a subject using a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for adhesion of a pathogen that causes said infection. Exemplary infection includes infection caused by a virus, bacterium, fungus, or protozoan.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: May 14, 2019
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Che-Ming Jack Hu
  • Patent number: 10183938
    Abstract: The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ?7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 22, 2019
    Assignee: Axovant Sciences GmbH
    Inventors: Raksha Acharya, Duane A. Burnett, Matthew Gregory Bursavich, Andrew Simon Cook, Bryce Alden Harrison, Gerhard Koenig, Andrew J. Mcriner
  • Patent number: 10085974
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 2, 2018
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • Patent number: 10058490
    Abstract: A composition that includes an activatable aggregate is described herein. The aggregate has a core and a shell. In some embodiments, when the aggregate is exposed to acoustic energy, the core of the aggregate includes a hydrogel that is capable of absorbing a relatively large amount of water. The core of the aggregate is covalently bound to a shell of linear aliphatic moieties. The aggregate is synthesized to minimize the amount of water in the core, prior to exposure to acoustic energy. Methods of hydrating using the compositions are also provided.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: August 28, 2018
    Assignee: L'Oreal
    Inventors: Vincenzo Casasanta, III, William Brenden Carlson, Gregory David Phelan
  • Patent number: 10034867
    Abstract: Provided is a powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 31, 2018
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 9993556
    Abstract: The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 12, 2018
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
  • Patent number: 9914729
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 13, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Joachim Luithle, Frank-Gerhard BÖβ, Christina Erb, Katrin Schnizler, Timo Flessner, Marja van Kampen, Christoph Methfessel
  • Patent number: 9867812
    Abstract: The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/or memory.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 16, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Timo Fleβner, Frank-Gerhard Böβ, Frank-Thorsten Hafner, Joachim Luithle, Christoph Methfessel, Leila Telan
  • Patent number: 9849117
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Patent number: 9809582
    Abstract: Compounds of formula (I) are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 7, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Wesley Blackaby, Herve Van De Poel, Charles Baker-Glenn, Naimisha Trivedi
  • Patent number: 9783527
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 10, 2017
    Assignee: AbbVie Inc.
    Inventors: Jerome F. Daanen, David A. DeGoey, Jennifer M. Frost, John R. Koenig, Steve Latshaw, Mark Matulenko, Marc Scanio, Lei Shi, William H. Bunnelle
  • Patent number: 9763924
    Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 19, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Carmelida Capaldi, Wesley Blackaby, Ian Linney, Hervé Van De Poël, Charles Baker-Glenn, Naimisha Trivedi
  • Patent number: 9687482
    Abstract: The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 27, 2017
    Assignee: CJ HEALTHCARE CORPORATION
    Inventors: Young Hee Suh, Young Dae Cho, Chun Seon Lyu, Mi Young Yoon, Ha Yong Choi, Sung Kyun Han
  • Patent number: 9687478
    Abstract: Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Type: Grant
    Filed: April 9, 2016
    Date of Patent: June 27, 2017
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 9592318
    Abstract: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional management alternatives (such as suturing and/or administration of injected or systemic analgesia) are impractical, unaffordable or otherwise unavailable.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 14, 2017
    Assignee: ANIMAL ETHICS PTY LTD
    Inventors: Meridith Sheil, Allan Giffard, Charles R. Olsson
  • Patent number: 9469606
    Abstract: This disclosure relates to inhibitors of the Wni pathway, and compositions comprising the same, as well as to their use in the treatment of disorders characterized by the activation of Writ pathway signaling (e.g., cancer), as well as to the modulation of cellular events mediated by VVnt pathway signaling.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: October 18, 2016
    Assignee: The General Hospital Corporation
    Inventors: Sam W. Lee, Anna I. Mandinova
  • Patent number: 9453013
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 27, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio Rancati, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Patent number: 9439853
    Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: September 13, 2016
    Assignee: BIOPROJET
    Inventors: Jean-Stëphane Julien, Marc Maury, Jeanne-Marie Lecomte, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Patent number: 9433614
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 6, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Joachim Luithle, Frank-Gerhard Bob, Christina Erb, Katrin Schnizler, Timo Flessner, Marja V. Kampen, Christoph Methfessel
  • Patent number: 9434724
    Abstract: Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating ?7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: September 6, 2016
    Assignee: ALPHARMAGEN, LLC
    Inventors: Geoffrey M. Bilcer, Raymond Ng
  • Patent number: 9371318
    Abstract: Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 21, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio Rancati, Ian Linney
  • Patent number: 9333195
    Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: May 10, 2016
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 9301956
    Abstract: 9-O-propargyl ethers of cinchona alkaloids of general formula represented by formula 1 wherein respective ethers have the following absolute configuration at C-8 and C-9 atoms: (8R,9S)-cinchonine configuration or (8R,9R)-9-epicinchonine configuration are useful in treatments of at least one of breast cancer, cervical cancer, lung cancer and nasopharynx cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: April 5, 2016
    Assignee: ADAM MICKIEWICZ UNIVERSITY
    Inventors: Lech Celewicz, Karol Kacprzak, Piotr Ruszkowski
  • Patent number: 9254262
    Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: February 9, 2016
    Assignee: Almirall, S.A.
    Inventors: Rosa Lamarca Casado, Gonzalo De Miquel Serra
  • Patent number: 9233951
    Abstract: The present invention relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which include arthropods and especially insects.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 12, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Friedrich August Mühlthau, Thomas Bretschneider, Reiner Fischer, Martin Füβlein, Markus Heil, Achim Hense, Joachim Kluth, Adeline Köhler, Eva-Maria Franken, Olga Malsam, Arnd Voerste, Peter Jeschke, Angela Becker, Peter Lösel, Yoshitaka Sato
  • Patent number: 9227964
    Abstract: The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/or memory.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: January 5, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Timo Fleβner, Frank-Gerhard Böβ, Frank-Thorsten Hafner, Joachim Luithle, Christoph Methfessel, Leila Telan
  • Patent number: 9173876
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 3, 2015
    Inventors: Merouane Bencherif, Nikolai Federov, Terry Hauser, Kristen G. Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
  • Patent number: 9169245
    Abstract: Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: October 27, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Mauro Riccaboni, Charles Baker-Glenn
  • Patent number: 9155733
    Abstract: Provided are tris-quaternary ammonium compounds which are modulators of nociception and pain.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: October 13, 2015
    Assignees: University of Kentucky Research Foundation, University of Utah
    Inventors: Joseph R. Holtman, Peter Anthony Crooks, Linda P. Dwoskin, J. Michael McIntosh
  • Patent number: 9119878
    Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 1, 2015
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventors: David A. Dill, Ilya A. Volfson
  • Patent number: 9056100
    Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide and methods of using the same.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: June 16, 2015
    Assignee: ALMIRALL, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 9040557
    Abstract: The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 26, 2015
    Assignee: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC.
    Inventor: Tae Sun Park
  • Publication number: 20150140099
    Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Sandrine Allain Ruiz, Beatriz Seoane Nunez, Gonzalo De Miguel Serra
  • Publication number: 20150139916
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Publication number: 20150132271
    Abstract: Cold and ready to eat beverage cakes, and with a variety of ingredient combinations are suitable for healthy consumption. The beverage cakes are soft in texture and high in nutrition. People can save the time and energy of preparing and cooking of the food. Serving size can be a single serving, and a six pack of servings. Beverage cakes are also created as beverage egg cakes, beverage plus salt source cakes, beverage seafood cakes, beverage meat cakes, beverage bubbles, beverage balls, beverage patties, and beverage sausages. They can be served as cold and hot food for breakfast, lunch, snack, and dinner. They can also be used as animal food, baby food, for children with less teeth, for elderly people, and for sick people. Cold and ready to eat beverage cakes with ingredients offer the consumers an easy and convenient way to obtain an affordable, nutritious, and delicious meal.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 14, 2015
    Inventor: Alice Chang
  • Publication number: 20150133491
    Abstract: Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Ian LINNEY
  • Publication number: 20150126547
    Abstract: A method of administering an effective amount of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 7, 2015
    Inventors: Dana C. Hilt, Gerhard Koenig
  • Publication number: 20150126546
    Abstract: A method for improving cognition comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor is described together with related compositions.
    Type: Application
    Filed: June 17, 2014
    Publication date: May 7, 2015
    Inventors: Gerhard Koenig, Dana Hilt
  • Publication number: 20150118312
    Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 30, 2015
    Inventors: Rosa Lamaraca Casado, Gonzalo De Miquel Serra
  • Publication number: 20150111901
    Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Cheol Young MAENG, Young Koo JANG, Su Bong CHA, Hye Won SHIN, Chan Mi JOUNG, Eun Jung YI
  • Publication number: 20150104516
    Abstract: Cohesive high-dosage strength micronized active ingredients may be dispersed in dry powder formulations for inhalation comprising carrier particles, by use of the apparatus described herein.
    Type: Application
    Filed: September 11, 2014
    Publication date: April 16, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Claudio CAFIERO, Federico TOSINI
  • Publication number: 20150105421
    Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
    Type: Application
    Filed: October 20, 2014
    Publication date: April 16, 2015
    Inventors: Merouane Bencherif, Nikolai Federov, Terry Hauser, Kristen G. Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
  • Patent number: 9000008
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: April 7, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Joachim Luithle, Frank-Gerhard Bob, Christina Erb, Katrin Schnizler, Timo Flessner, Marja V. Kampen, Christoph Methfessel
  • Publication number: 20150093374
    Abstract: The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Applicant: ALMIRALL S.A.
    Inventor: Jorge Beleta SUPERVIA
  • Patent number: 8993556
    Abstract: The present invention relates to substituted resorcinol derivatives which inhibit the activity of Heat Shock Protein HSP90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, pharmaceutical compositions comprising them, methods of treating diseases and the pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: March 31, 2015
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Maria Gabriella Brasca, Elena Casale, Ron Ferguson, Paolo Polucci, Fabio Zuccotto
  • Publication number: 20150083127
    Abstract: The present invention relates to aggregate particles comprising nanoparticulate drug particles. In particular, the present invention is directed to aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide and optionally vilanterol trifenatate and/or fluticasone furoate. Aggregate particles of the present invention may further comprise nanoparticulate excipient particles and one or more binders. The invention also relates to powder compositions suitable for inhalation that comprise said aggregate particles, processes of producing said aggregate particles, and use of said powder compositions in the treatment of respiratory diseases, such as asthma and COPD.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 26, 2015
    Inventors: Michiel Mary Van Oort, John N. Hong
  • Publication number: 20150087626
    Abstract: There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.
    Type: Application
    Filed: July 4, 2011
    Publication date: March 26, 2015
    Inventors: Manuela Borriello, Sabrina Pucci, Luigi Piero Stasi, Lucio Rovati